Saleem A. Farooqui
Pfizer R&D UK Ltd
Sandwich, ENG, United Kingdom
Sandwich, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.
Journal: Dermatology and therapy
Published: February 05, 2026
Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 31, 2025
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
Journal: American journal of clinical dermatology
Published: May 01, 2024
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 10, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 10, 2023
Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
Journal: The Journal of dermatological treatment
Published: June 28, 2022
Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers.
Journal: Clinical pharmacology in drug development
Published: December 20, 2021
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Journal: American journal of clinical dermatology
Published: October 13, 2021
High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 26, 2021
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: June 27, 2021
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Journal: American journal of clinical dermatology
Published: June 16, 2021
18F-FDG PET/CT Imaging of Extranodal Rosai-Dorfman Disease with Hepatopancreatic Involvement - A Pictorial and Literature Review.
Journal: Cureus
Published: January 23, 2016
Last Updated: 09/26/2026